President Trump signed S. 3971, reauthorizing the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs through 2031. The legislation includes reforms to strengthen national security, accountability, and innovation. Since 1982, these programs have invested over $81 billion into 34,000+ small businesses and supported major companies including Anduril, Qualcomm, Biogen, Illumina, and iRobot.

The global NGS market is projected to reach USD 29.53 billion by 2030 from USD 14.94 billion in 2025, growing at a CAGR of 14.6%. Growth is driven by expanding applications in oncology, infectious diseases, and precision medicine, with Asia-Pacific exhibiting the fastest regional growth. Consumables dominate the product segment, while academic and research institutes lead the services end-user segment.

The global DNA read, write and edit market is projected to grow from $21.4 billion in 2024 to $67.7 billion by 2030 at a 21.2% CAGR, driven by expanding clinical applications of genome editing, genomic diagnostics demand, and CRISPR-based therapeutics investment. North America leads with 43.5% market share.

The global molecular diagnostics market is projected to grow from USD 18.26 billion in 2025 to USD 43.50 billion by 2035, with a CAGR of 9.07%. Growth is driven by increasing demand for early and accurate disease detection, rising prevalence of chronic diseases, and adoption of advanced technologies like PCR and next-generation sequencing. The U.S. market is expected to grow from USD 5.0 billion to USD 8.07 billion during the same period.

The global oncology biomarkers market is projected to grow from $17.3 billion in 2025 to $33.63 billion by 2030, with a CAGR of 14.3%. Growth is driven by rising cancer incidence, personalized oncology therapies, AI-driven biomarker discovery, liquid biopsy adoption, and early cancer detection focus. Key players include Roche, Novartis, and Thermo Fisher Scientific.

Sessa Capital invested $175.8 million in Sotera Health by purchasing 10.6 million shares in Q4, bringing its total stake to 20.55 million shares valued at $362.5 million. Despite a 21% stock decline, the investment signals confidence in the company's fundamentals, which include $1.2 billion in revenue and steady 20-year growth, though the stock faces headwinds from litigation risks, high leverage, and a recent secondary offering that flooded the market with shares.

The global molecular diagnostics market is projected to reach USD 33.51 billion by 2031, growing at a CAGR of 10.43% from 2026 to 2031. Growth is driven by increasing adoption of precision medicine, advancements in genomic testing technologies, and rising prevalence of infectious and chronic diseases. North America leads the market while Asia-Pacific is expected to be the fastest-growing region.

The global genomics services market is expected to grow from USD 7.94 billion in 2025 to USD 25.18 billion by 2035, with a CAGR of 11.8%. Growth is driven by increasing genetic disorder prevalence, government-funded precision medicine initiatives, and rising adoption of NGS-based diagnostics. The U.S. market alone is projected to reach USD 10.04 billion by 2035. Next-generation sequencing dominates with 38.42% market share, while Asia Pacific shows the fastest growth at 13.84% CAGR.

Corvex Management sold its entire 4.18 million share position in MDU Resources Group (worth $74.5 million) in Q4 2025, reallocating capital toward higher-growth holdings like Illumina and Amazon. The exit reflects a preference for asymmetric growth over the predictability of regulated utilities, despite MDU's solid fundamentals including 16% rate base growth and a $3.1 billion capital plan through 2030.

The precision medicine market is projected to grow from USD 110.68 billion in 2025 to USD 237.28 billion by 2031, with a CAGR of 13.58%. Growth is driven by AI integration, biomarker advancements, next-gen sequencing (35%+ market share), and expanding adoption of targeted oncology therapies. North America leads the market, while Asia-Pacific emerges as a high-growth region.

The global single nucleotide polymorphism (SNP) genotyping market is valued at USD 8.08 billion in 2026 and is expected to reach USD 19.48 billion by 2034, growing at an 11.7% CAGR. North America leads the market while Asia Pacific shows the fastest growth. PCR-based genotyping dominates by technology, pharmacogenomics leads by application, and pharmaceutical companies are the primary end users. Key drivers include personalized medicine adoption, technological advancements, and increased genomics research investments.

Standard BioTools Inc. (NASDAQ: LAB) announced it will release its fourth quarter and full year 2025 financial results on February 24, 2026. The company also completed the sale of SomaLogic to Illumina for $350 million upfront with up to $425 million in total proceeds, leaving the company with approximately $550 million in cash and cash equivalents.